TCTao Chen

Tao Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tao Chen has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Yu-Hai Wang

    Department of Neurosurgery, the 904th Hospital of Joint Logistic Support Force of PLA, Wuxi Clinical College of Anhui Medical University, Wuxi, China

    8 shared publications
  • Jie Zhu

    Department of Neurosurgery, The 904Th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, China

    7 shared publications
  • Xiao Qian

    Department of Neurosurgery, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, Jiangsu, 214044, China

    4 shared publications
  • Ao Li

    Department of Neurosurgery, the 904th Hospital of Joint Logistic Support Force of PLA, Wuxi Clinical College of Anhui Medical University, Wuxi, China

    3 shared publications
  • Li-Kun Yang

    Department of Neurosurgery, The 904Th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, China

    3 shared publications
  • Yuhai Wang

    Department of Neurosurgery, The 904th Hospital of PLA, Medical School of Anhui Medical University, Wuxi, Jiangsu, 214044, China

    3 shared publications

Latest Publications

  • Open Access

    Topiramate protects against neuroinflammation in response to traumatic brain injury via activating Sirt1 signaling

    by Xu Zhang, Ao Li, Ying Zhang, Wen-Kai Wu, Zhi-Zhong Yan, Tao Chen, Yu-Hai Wang

    Traumatic brain injury (TBI) elicits a sustained neuroinflammatory cascade that contributes to neuronal loss and poor functional recovery. Topiramate (TPM) is an FDA-approved antiepileptic drug with anti-excitotoxic and anti-inflammatory actions. Here, we tested whether TPM mitigates neuroinflammation and improves outcomes in experimental TBI models. Adult mice subjected to controlled cortical impact (CCI) received TPM (80 mg/kg, i.p.) 30 min post-injury and every 12 h for 48 h. Outcomes included neuronal survival, brain water content, neurological function, lipid peroxidation, inflammatory cytokines expression, astrocyte and microglia activation. The potential underlying mechanism was determined by measuring microglial polarization markers and neuronal Sirt1 expression. A traumatic neuronal injury (TNI) model in primary cortical neurons assessed dose (10–100 µM TPM) and therapeutic window (0–4 h post-injury). The Sirt1 inhibitor sirtinol was used in vivo and in vitro to probe mechanism. The results showed that TPM reduced neuronal loss, ipsilateral brain water content, and cleaved caspase-3, and improved mNSS and beam-walk performance on days 7 and 14. TPM decreased levels of MDA, 4-HNE, TNF-α, IL-1β, and IL-6 while increasing IL-10 expression, and suppressed GFAP⁺ astrocytosis and Iba-1⁺ microgliosis. Notably, TPM shifted microglial phenotype toward an M2-like state and enhanced nuclear Sirt1 expression in neurons. Sirtinol attenuated TPM-induced protection and partly reversed the TPM-induced changes in microglial polarization markers. In vitro, TPM (50–100 µM) reduced LDH release, preserved calcein signal, and inhibited lipid peroxidation, with efficacy observed when administered within 2 h post-injury, which were blunted by sirtinol. In summary, these data indicate that TPM confers neuroprotection after TBI, at least in part, by engaging Sirt1 and promoting a pro-resolving microglial phenotype, supporting its therapeutic potential for the treatment of TBI.

  • Open Access

    Study on the Function and Mechanism of Neutrophil Extracellular Traps in Regulating Necroptosis Following Traumatic Brain Injury

    by Ao Li, Tian‐Wei Pei, Hao Qi, Li‐Biao Song, Juan Fang, Zhi‐Song Ding, Tao Chen

    Purpose: Traumatic brain injury (TBI) remains a major global public health challenge with high morbidity and mortality, and secondary injury characterized by neuroinflammation, brain edema, and neuronal cell death is a critical determinant of patient prognosis. Neutrophil extracellular traps (NETs) and necroptosis are involved in TBI pathology, but their crosstalk remains unclear. Here, we used NETs inhibitors (Cl‐amidine and DNase I) and the necroptosis inhibitor Necrostatin‐1 (Nec‐1) to investigate the roles of NETs and necroptosis in neuronal injury following TBI. Method: Male C57BL/6J mice were used to establish a TBI model via controlled cortical impact (CCI). Cl‐amidine, DNase I, and Necrostatin‐1 were administered to explore the mechanism by which NETs regulate necroptosis and exacerbate TBI‐induced secondary injury. The modified neurological severity score (mNSS) assessment, brain edema measurement, enzyme‐linked immunosorbent assay (ELISA), Western blotting, immunofluorescence staining, and TUNEL staining were performed in this study. Mice were sacrificed at 1, 3, 5, and 7 days post‐TBI, with Day 3 post‐TBI designated as the key time point for primary analyses due to the peak expression of NETs markers: myeloperoxidase (MPO) and peptidyl arginine deiminase 4 (PAD4). Finding: Our results showed that TBI induced a time‐dependent upregulation of MPO and PAD4 in the ipsilateral cortex. Inhibition of NETs or blockade of necroptosis significantly reduced neuronal apoptosis, alleviated brain edema, improved mNSS scores, preserved blood–brain barrier integrity, and decreased levels of pro‐inflammatory cytokines (TNF‐α, IL‐1β). Western blot analysis revealed that TBI markedly upregulated the expression of RIP1, RIP3, MLKL, and their phosphorylated forms, while NETs inhibition downregulated these necroptosis‐related proteins. Notably, combined inhibition of NETs and necroptosis did not exert synergistic protective effects on TBI‐induced brain injury. Conclusion: NETs exacerbate TBI‐induced secondary brain injury partially by activating the necroptosis pathway. Inhibition of NETs exerts neuroprotective effects. Targeting NETs may serve as a promising therapeutic strategy to improve prognosis in TBI patients.


  • Integrated Necroptosis Within Programmed Cell Death in Traumatic Brain Injury

    by Ao Li, Tian-Wei Pei, Hao Qi, Juan Fang, Zhi-Song Ding, Yu Wang, Yu-Qiang Zhang, Tao Chen

    Traumatic brain injury (TBI), a major global public health burden, is characterized by complex pathophysiology involving primary and secondary injuries, with programmed cell death (PCD) pathways significantly impacting neuronal damage and neurological dysfunction. Substantial evidence over time highlights necroptosis—a caspase-independent, inflammatory form of PCD mediated by RIPK1/RIPK3/MLKL—as a key driver of secondary injury after TBI. However, the dynamic interplay between necroptosis and other PCD pathways after TBI remains poorly understood. In this review, we systematically describe the mechanisms involving necroptosis in TBI and its potential therapeutic targets, while delving into the interplay and regulatory relationships between necroptosis and other PCD pathways, including apoptosis, autophagy, pyroptosis, and ferroptosis. Future investigations and the formulation of therapeutic approaches for TBI should comprehensively consider the complex characteristics of necroptosis and its interplay with other pathways.

  • Open Access

    T817MA regulates mitochondrial dynamics via Sirt1 and Arc following subarachnoid hemorrhage

    by Wei-Wei Chen, Fu-Qiang Sun, Bo Wang, Xiao-Xiao Tian, Rong-Ping Zhang, Wen-Bo Liu, Tao Chen

    Spontaneous subarachnoid hemorrhage (SAH) is an acute neurologic emergency with poor outcomes, and mitochondrial dysfunction is known as one of the key pathological mechanisms underlying the SAH-induced early brain injury (EBI). 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate (T817MA) is a newly synthesized neurotrophic compound that has been demonstrated to exert protective effects against brain injury. Here, we investigated the effect of T817MA in neuronal injury following experimental SAH both in vitro and in vivo. Primary cultured cortical neurons were treated with oxyhemoglobin(OxyHb) to mimic SAH in vitro, and T817MA at concentrations higher than 0.1 μM reduced OxyHb-induced neuronal injury. T817MA treatment significantly inhibited lipid peroxidation, reduced neuronal apoptosis and attenuated mitochondrial fragmentation. The results of western blot showed that T817MA markedly reduced the expression of mitochondrial fission proteins, fission protein 1 (Fis-1) and dynamin-related GTPase-1 (Drp-1), but prolonged the expression of the postsynaptic protein activity-regulated cytoskeleton-associated protein (Arc). In addition, T817MA significantly increased the expression of sirtuin 1 (Sirt1), which was accompanied by preserved enzymatic of isocitrate dehydrogenase (IDH2) and superoxide dismutase (SOD). Knockdown of Sirt1 and Arc via small interfere RNA (siRNA) transfection partially prevented the T817MA-induced protection in cortical neurons. Furthermore, treatment with T817MA in vivo significantly reduced brain damage and preserved neurological function in rats. The decreased expression of Fis-1 and Drp-1, as well as the increased expression of Arc and Sirt1 were also observed in vivo. Taken together, these data indicate that the neuroprotective agent T817MA protects against SAH-induced brain injury via Sirt1- and Arc-mediated regulation of mitochondrial dynamics.

  • Open Access

    Microglial polarization in TBI: Signaling pathways and influencing pharmaceuticals

    by Yun-Fei Li, Xu Ren, Liang Zhang, Yu-Hai Wang, Tao Chen

    Traumatic brain injury (TBI) is a serious disease that threatens life and health of people. It poses a great economic burden on the healthcare system. Thus, seeking effective therapy to cure a patient with TBI is a matter of great urgency. Microglia are macrophages in the central nervous system (CNS) and play an important role in neuroinflammation. When TBI occurs, the human body environment changes dramatically and microglia polarize to one of two different phenotypes: M1 and M2. M1 microglia play a role in promoting the development of inflammation, while M2 microglia play a role in inhibiting inflammation. How to regulate the polarization direction of microglia is of great significance for the treatment of patients with TBI. The polarization of microglia involves many cellular signal transduction pathways, such as the TLR-4/NF-κB, JAK/STAT, HMGB1, MAPK, and PPAR-γ pathways. These provide a theoretical basis for us to seek therapeutic drugs for the patient with TBI. There are several drugs that target these pathways, including fingolimod, minocycline, Tak-242 and erythropoietin (EPO), and CSF-1. In this study, we will review signaling pathways involved in microglial polarization and medications that influence this process.


  • Open Access

    Edonerpic maleate regulates glutamate receptors through CRMP2- and Arc-mediated mechanisms in response to brain trauma

    by Tao Chen, Li-Kun Yang, Pu Ai, Jie Zhu, Chun-Hua Hang, Yu-Hai Wang

    Dysfunction of ionotropic glutamate receptors (iGluRs) is a key molecular mechanism of excitotoxic neuronal injury following traumatic brain injury (TBI). Edonerpic maleate is a low molecular-weight compound that was screened as a candidate neuroprotective agent. In this study, we investigated its effects on TBI and GluRs signaling. Traumatic neuronal injury (TNI) induced by scratch followed by glutamate treatment was performed to mimic TBI in vitro. Edonerpic maleate at 1 and 10 μM exerted protective activity when it was added within 2 h following injury. The protective activities were also confirmed by the reduction of lipid peroxidation and oxidative stress. In addition, edonerpic maleate inhibited the expression of surface NR2B, total GluR1, and surface GluR1, and mitigated the intracellular Ca2+ responses following injury in vitro. Western blot analysis showed that edonerpic maleate reduced the cleavage of collapsing response mediator protein 2 (CRMP2), but increased the expression of postsynaptic protein Arc. By using gene overexpression and silencing technologies, CRMP2 was overexpressed and Arc was knockdown in cortical neurons. The results showed that the effect of edonerpic maleate on NMDA receptor expression was mediated by CRMP2, whereas the edonerpic maleate-induced AMPA receptor regulation was dependent on Arc activation. In in vivo TBI model, 30 mg/kg edonerpic maleate alleviated the TBI-induced brain edema, neuronal loss, and microglial activation, with no effect on locomotor function at 24 h. However, edonerpic maleate improves long-term neurological function after TBI. Furthermore, edonerpic maleate inhibited CRMP2 cleavage but increased Arc activation in vivo. In summary, our results identify edonerpic maleate as a clinically potent small compound with which to attenuate TBI-related brain damage through regulating GluRs signaling.